HEART TRANSPLANTATION Pediatric Recipients ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

NUMBER OF CENTERS REPORTING PEDIATRIC HEART TRANSPLANTS ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

AVERAGE CENTER VOLUME AND PERCENTAGE OF TRANSPLANTS BY CENTER VOLUME Pediatric Heart Transplants: January 1, June 30, 2011 ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Distribution of Transplants By Location and Average Center Volume (Transplants: January 2000 – June 2011) ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

DISTRIBUTION OF TRANSPLANTS By Center Volume Pediatric Heart Transplants: January 1, June 30, 2011 ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

AGE DISTRIBUTION OF PEDIATRIC HEART RECIPIENTS (Transplants: January June 2011) ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

AGE DISTRIBUTION OF PEDIATRIC HEART RECIPIENTS By Year of Transplant ISHLT 2012 NOTE: This figure includes only the heart transplants that are reported to the ISHLT Transplant Registry. As such, this should not be construed as evidence that the number of hearts transplanted worldwide has increased and/or decreased in recent years. J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Age Distribution By Location (Transplants: January 2000 – June 2011) ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

AGE DISTRIBUTION FOR DONORS OF PEDIATRIC HEART RECIPIENTS (Transplants: January June 2011) ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Donor Age Distribution By Location (Transplants: January 2000 – June 2011) ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

DISTRIBUTION OF TRANSPLANTS by Donor/Recipient Weight Ratio (Pediatric Heart Transplants: January 1, June 30, 2011) ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

DIAGNOSIS IN PEDIATRIC HEART TRANSPLANT RECIPIENTS (Age: < 1 Year) ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

DIAGNOSIS IN PEDIATRIC HEART TRANSPLANT RECIPIENTS (Age: 1-10 Years) ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

DIAGNOSIS IN PEDIATRIC HEART TRANSPLANT RECIPIENTS (Age: Years) ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Diagnosis Distribution By Location (Transplants: January 2000 – June 2011) ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART RECIPIENTS % of Patients Bridged with Mechanical Circulatory Support* by Year (Transplants: January 2005 – December 2010) ISHLT 2012 * LVAD, RVAD, TAH, ECMO J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART RECIPIENTS % of Patients Bridged with Mechanical Circulatory Support* (Transplants: July 2004 – June 2011) ISHLT 2012 * LVAD, RVAD, TAH, ECMO J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART RECIPIENTS % of Patients Bridged with Mechanical Circulatory Support* by Age Group (Transplants: July 2004 – June 2011) ISHLT 2012 * LVAD, RVAD, TAH, ECMO J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART RECIPIENTS PRA Distribution by Year (Transplants: 2005 – 2010) ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART RECIPIENTS PRA Distribution by Age Group (Transplants: July 2004 – June 2011) ISHLT 2012 p-value = J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Kaplan-Meier Survival (Transplants: 1/1982-6/2010) ISHLT <1 vs. 1-10: p = <1 vs : p = vs : p = J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Conditional Kaplan-Meier Survival (Transplants: 1/1982-6/2010) ISHLT <1 vs. 1-10: p = <1 vs : p < vs : p < J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Kaplan-Meier Survival by Era (Transplants: 1/1982-6/2010) ISHLT 2012 All p-values significant at p = J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Conditional Kaplan-Meier Survival for Recent Era (Transplants: 1/2000-6/2010) ISHLT <1 vs. 1-10: p = <1 vs : p = vs : p < J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Kaplan-Meier Survival by Era (Transplants: 1/1982-6/2010) Age: < 1 Year ISHLT vs : p = vs /2010: p < vs /2010: p < Half-life : 10.8 years; : 18.3 years; /2010: n.c. J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Kaplan-Meier Survival by Era (Transplants: 1/1982-6/2010) Age: 1-10 Years ISHLT 2012 All p-values significant at p = Half-life : 8.0; : 14.3; /2010: n.c. J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Kaplan-Meier Survival by Era (Transplants: 1/1982-6/2010) Age: Years ISHLT vs : p = vs /2010: p < vs /2010: p = Half-life : 9.3; : 11.4; /2010: n.c. J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Kaplan-Meier Survival by Diagnosis (Transplants: /2010) Age: < 1 Year ISHLT 2012 p-value < J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Kaplan-Meier Survival by Diagnosis (Transplants: /2010) Age: Years ISHLT 2012 Congenital vs. Cardiomyopathy: p < Congenital vs. Retransplant: p = Cardiomyopathy vs. Retransplant: p < J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Kaplan-Meier Survival by Diagnosis (Transplants: /2010) Age: Years ISHLT 2012 Congenital vs. Cardiomyopathy: p = Congenital vs. Retransplant: p = Cardiomyopathy vs. Retransplant: p= J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Kaplan-Meier Patient vs. Graft Survival (Transplants: 1/2000-6/2010) Average Center Volume: 1-4 Transplants per Year ISHLT 2012 p = J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Kaplan-Meier Patient vs. Graft Survival (Transplants: 1/2000-6/2010) Average Center Volume: 5-9 Transplants per Year ISHLT 2012 p = J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Kaplan-Meier Patient vs. Graft Survival (Transplants: 1/2000-6/2010) Average Center Volume: 10+ Transplants per Year ISHLT 2012 p = J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART RECIPIENTS Cross-Sectional Analysis Functional Status of Surviving Recipients (Follow-ups: January 2000 – June 2011) ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART RECIPIENTS Functional Status of Surviving Recipients (Follow-ups: January 2000 – June 2011) Age: <1 Year ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART RECIPIENTS Functional Status of Surviving Recipients (Follow-ups: January 2000 – June 2011) Age: 1-10 Years ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART RECIPIENTS Functional Status of Surviving Recipients (Follow-ups: January 2000 – June 2011) Age: Years ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART RECIPIENTS Functional Status of Surviving Recipients US Recipients Only (Follow-ups: March 2005 – June 2011) ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART RECIPIENTS Rehospitalization Post-transplant of Surviving Recipients (Follow-ups: January 2000 – June 2011) ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART RECIPIENTS Induction Immunosuppression (T ransplants: January 2001 – June 2011) ISHLT 2012 Analysis is limited to patients who were alive at the time of the discharge J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART RECIPIENTS Induction Immunosuppression (Transplants: January 2001 – June 30, 2011) ISHLT 2012 Analysis is limited to patients who were alive at the time of the discharge Test of increasing trend over time: Any induction p < Polyclonal p < IL-2R p < J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Kaplan-Meier Survival by Induction Group Conditional on Survival to 14 Days (Transplants: January 2000 – June 2010) ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Kaplan-Meier Survival by Induction Group and Treated Rejection Between Transplant Discharge and 1-Year Follow-up (1-Year Follow-ups: July June 2010) Conditional on Survival to 1 Year ISHLT 2012 Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti- rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Kaplan-Meier Survival by Induction Group Conditional on Survival to 14 Days (Transplants: January 2000 – June 2010) Age: <1 Year ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Kaplan-Meier Survival by Induction Group Conditional on Survival to 14 Days (Transplants: January 2000 – June 2010) Age: 1-10 Years ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Kaplan-Meier Survival by Induction Group Conditional on Survival to 14 Days (Transplants: January 2000 – June 2010) Age: Years ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART RECIPIENTS Maintenance Immunosuppression at Time of Follow-up (Follow-ups: January 2001 – June 2011) ISHLT 2012 Analysis is limited to patients who were alive at the time of the follow-up J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART RECIPIENTS Maintenance Immunosuppression at Time of Follow-up for Same Patients at Each Time Point (Follow-ups: January 2001 – June 2011) ISHLT 2012 Analysis is limited to patients who were alive at the time of the follow-up J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART RECIPIENTS Maintenance Immunosuppression Drug Combinations at Time of Follow-up (Follow-ups: January 2001 – June 2011) ISHLT 2012 Analysis is limited to patients who were alive at the time of the follow-up NOTE: Different patients are analyzed in Year 1 and Year 5 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Kaplan-Meier Survival Based on Prednisone Use Conditional on Survival to 1 Year (Transplants: January June 2010) ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Kaplan-Meier Survival Stratified by Tacrolimus vs. Cyclosporine Use at Discharge Conditional on Survival to 14 Days (Transplants: January June 2010) ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Kaplan-Meier Survival Stratified by Tacrolimus vs. Cyclosporine Use Conditional on Survival to 1 Year (Transplants: January June 2010) ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Kaplan-Meier Survival Based on Treated Rejection within 1 st Year Conditional on survival to 1 year (1-Year Follow-ups: July June 2010) ISHLT 2012 Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti- rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Kaplan-Meier Survival Based on Treated Rejection within 1 st Year Stratified by Calcineurin Use at Discharge Conditional on survival to 1 year (1-Year Follow-ups: July June 2010) ISHLT 2012 Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti- rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Kaplan-Meier Survival Based on Treated Rejection within 1 st Year Stratified by Calcineurin Use at Discharge: Age = 0-10 Years Conditional on survival to 1 year (1-Year Follow-ups: July June 2010) ISHLT 2012 Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti- rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS Kaplan-Meier Survival Based on Treated Rejection within 1 st Year Stratified by Calcineurin Use at Discharge: Age = Years Conditional on survival to 1 year (1-Year Follow-ups: July June 2010) ISHLT 2012 Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti- rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. J Heart Lung Transplant Oct; 31(10):

PERCENTAGE OF PEDIATRIC HEART TRANSPLANT RECIPIENTS Experiencing Rejection between Transplant Discharge and 1-Year Follow-Up Stratified by Era (Follow-ups: July June 2011) ISHLT 2012 Analysis is limited to patients who were alive at the time of the follow-up Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. J Heart Lung Transplant Oct; 31(10):

PERCENTAGE OF PEDIATRIC HEART TRANSPLANT RECIPIENTS Experiencing Rejection between Transplant Discharge and 1-Year Follow-Up Stratified by Induction (Follow-ups: July June 2011) ISHLT 2012 Analysis is limited to patients who were alive at the time of the follow-up Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. J Heart Lung Transplant Oct; 31(10):

PERCENTAGE OF PEDIATRIC HEART TRANSPLANT RECIPIENTS Experiencing Rejection between Transplant Discharge and 1-Year Follow-Up Stratified by Type of Induction (Follow-ups: July June 2011) ISHLT 2012 Analysis is limited to patients who were alive at the time of the follow-up Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. J Heart Lung Transplant Oct; 31(10):

PERCENTAGE OF PEDIATRIC HEART TRANSPLANT RECIPIENTS Experiencing Rejection between Transplant Discharge and 1-Year Follow-Up Stratified by Maintenance Immunosuppression and Induction (Follow-ups: July June 2011) ISHLT 2012 Analysis is limited to patients who were alive at the time of the follow-up Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti- rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. J Heart Lung Transplant Oct; 31(10):

PERCENTAGE OF PEDIATRIC HEART TRANSPLANT RECIPIENTS Experiencing Rejection between Transplant Discharge and 1-Year Follow-Up Stratified by Maintenance Immunosuppression (Follow-ups: July June 2011) ISHLT 2012 Analysis is limited to patients who were alive at the time of the follow-up Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti- rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. J Heart Lung Transplant Oct; 31(10):

PERCENTAGE OF PEDIATRIC HEART TRANSPLANT RECIPIENTS Experiencing Rejection between Transplant Discharge and 1-Year Follow-Up Stratified by Stratified by Calcineurin Inhibitor Use at Discharge (Follow-ups: July June 2011) ISHLT 2012 Analysis is limited to patients who were alive at the time of the follow-up Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. J Heart Lung Transplant Oct; 31(10):

Freedom from Coronary Artery Vasculopathy For Pediatric Heart Recipients (Follow-ups: April 1994 – June 2011) ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

Freedom from Coronary Artery Vasculopathy For Pediatric Heart Recipients (Follow-ups: April 1994 – June 2011) Stratified by Induction ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

Freedom from Coronary Artery Vasculopathy For Pediatric Heart Recipients (Follow-ups: 2000 – June 2011) Stratified by Tacrolimus vs. Cyclosporine Use Conditional on Survival to 1 Year ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

Freedom from Coronary Artery Vasculopathy For Pediatric Heart Recipients (Follow-ups: 2000 – June 2011) Stratified by Age Group ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

Freedom from Coronary Artery Vasculopathy For Pediatric Heart Recipients (Follow-ups: 2000 – June 2011) Stratified by Ischemia Time ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

Freedom from Coronary Artery Vasculopathy For Pediatric Heart Recipients (Follow-ups: 2000 – June 2011) Stratified by Ischemia Time and Recipient Age ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

Graft Survival Following Report of Coronary Artery Vasculopathy For Pediatric Heart Recipients (Follow-ups: 2000 – June 2011) Stratified by Age Group ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

Freedom from Severe Renal Dysfunction* For Pediatric Heart Recipients (Follow-ups: 2000 – June 2011) ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

Freedom from Severe Renal Dysfunction* For Pediatric Heart Recipients (Follow-ups: 2000 – June 2011) Stratified by Tacrolimus vs. Cyclosporine Use Conditional on Survival to 1 Year ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

Freedom from Renal Replacement Therapy For Pediatric Heart Recipients (Follow-ups: April 1994 – June 2011) ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

Malignancy Post-Heart Transplant for Pediatrics Cumulative Morbidity Rates in Survivors (Follow-ups: April 1994 – June 2011) Malignancy/Type 1-Year Survivors 5-Year Survivors 10-Year Survivors No Malignancy 4,358 (98.3%)1,900 (95.1%)579 (91.2%) Malignancy (all types combined) 76 (1.7%)97 (4.9%)56 (8.8%) Malignancy Type* Lymphoma Other 554 Skin 011 Type Not Reported 100 *Recipients may have experienced more than one type of malignancy so sum of individual malignancy types may be greater than total number with malignancy. ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

FREEDOM FROM MALIGNANCY For Pediatric Heart Recipients (Follow-ups: April 1994 – June 2011) ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

FREEDOM FROM MALIGNANCY by Maintenance Immunosuppression Combinations at Discharge For Pediatric Heart Recipients (Follow-ups: January June 2011) Conditional on Survival to 1 year ISHLT 2012 p = J Heart Lung Transplant Oct; 31(10):

FREEDOM FROM LYMPHOMA BY INDUCTION For Pediatric Heart Recipients (Follow-ups: April 1994 – June 2011) ISHLT 2012 p = J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART RECIPIENTS Incidence of Hypertension between 1 and 3 Years (Transplants: January June 2008) Maintenance Immunosuppression at discharge and 1 year % HTN reported between 1 and 3 years P-value For Patients on drug For Patients not on drug Azathioprine Cyclosporine MMF/MPA Prednisone Sirolimus/Everolimus Tacrolimus J Heart Lung Transplant Oct; 31(10): ISHLT 2012

PEDIATRIC HEART RECIPIENTS Incidence of Hypertension between 3 and 5 Years (Transplants: January June 2006) Maintenance Immunosuppression at discharge and 1 year % HTN reported between 3 and 5 years P-value For Patients on drug For Patients not on drug Azathioprine Cyclosporine MMF/MPA Prednisone Sirolimus/Everolimus > Tacrolimus ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART RECIPIENTS Relationship of Rejection and Coronary Artery Vasculopathy (Follow-ups: July 2004 – June 2011) Rejection During 1 st Year Reported CAV between 1 st and 3 rd years post-transplant YesNo All Yes17 5.4% % % No25 4.6% % % p = ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART RETRANSPLANTS Kaplan-Meier Survival Rates Stratified by Inter-Transplant Interval (Re-transplants: January June 2010) Only patients who were less than 18 years old at the time of re-transplant are included. ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART RE-TRANSPLANTS By Transplant Year (Re-transplants: January 1994 – December 2010) Only patients who were less than 18 years old at the time of re-transplant are included. ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART RE-TRANSPLANTS By Inter-transplant Interval (Re-transplants: January June 2011) Only patients who were less than 18 years old at the time of re-transplant are included. Analysis is based on the age at the time of re-transplant ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANT RECIPIENTS: Cause of Death (Deaths: January June 2011) CAUSE OF DEATH 0-30 Days (N = 240) 31 Days - 1 Year (N = 282) >1 Year - 3 Years (N = 240) >3 Years - 5 Years (N = 191) >5 Years - 10 Years (N = 335) >10 Years (N = 262) CORONARY ARTERY VASCULOPATHY 3 (1.3%)14 (5.0%)40 (16.7%)47 (24.6%)84 (25.1%)71 (27.1%) ACUTE REJECTION22 (9.2%)50 (17.7%)47 (19.6%)24 (12.6%)43 (12.8%)13 (5.0%) LYMPHOMA 6 (2.1%)5 (2.1%)7 (3.7%)26 (7.8%)20 (7.6%) MALIGNANCY, OTHER 1 (0.4%)3 (1.3%)1 (0.5%)5 (1.5%)10 (3.8%) CMV 7 (2.5%)1 (0.4%) INFECTION, NON-CMV30 (12.5%)37 (13.1%)16 (6.7%)8 (4.2%)14 (4.2%)18 (6.9%) GRAFT FAILURE80 (33.3%)42 (14.9%)74 (30.8%)66 (34.6%)106 (31.6%)75 (28.6%) TECHNICAL20 (8.3%)2 (0.7%)1 (0.4%)1 (0.5%)4 (1.2%)6 (2.3%) OTHER16 (6.7%)23 (8.2%)27 (11.3%)16 (8.4%)26 (7.8%)21 (8.0%) MULTIPLE ORGAN FAILURE 32 (13.3%)53 (18.8%)11 (4.6%)8 (4.2%)9 (2.7%)11 (4.2%) RENAL FAILURE 7 (2.5%)1 (0.4%)1 (0.5%)1 (0.3%)7 (2.7%) PULMONARY11 (4.6%)27 (9.6%)10 (4.2%)7 (3.7%)10 (3.0%)6 (2.3%) CEREBROVASCULAR26 (10.8%)13 (4.6%)4 (1.7%)5 (2.6%)7 (2.1%)4 (1.5%) ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANT RECIPIENTS: Relative Incidence of Leading Causes of Death (Deaths: January June 2011) ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 1 Year Mortality VARIABLE NRelative Risk P-value95% Confidence Interval ECMO, age = 0 years < Retransplant Congenital diagnosis < ECMO, age = 1-17 years On dialysis On ventilator Prior sternotomy Donor cause of death = cerebrovascular/stroke vs. head trauma Male donor/female recip vs. male donor/male recip Previous transfusions Donor cause of death = anoxia vs. head trauma N = 3,417 Reference group = Cardiomyopathy, no devices ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS ( ) Borderline Significant Risk Factors For 1 Year Mortality N = 3,417 ISHLT 2012 VARIABLEN Relative Risk P-value 95% Confidence Interval Donor with prior clinical infection J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 1 Year Mortality Continuous Factors (see figures) Donor ageIschemia time Recipient pre-transplant creatinine ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 1 Year Mortality with 95% Confidence Limits Donor Age p = ISHLT 2012 (N = 3,417) J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 1 Year Mortality with 95% Confidence Limits Recipient Pre-Transplant Creatinine p = ISHLT 2012 (N = 3,417) J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 1 Year Mortality with 95% Confidence Limits Ischemia time p = ISHLT 2012 (N = 3,417) J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS ( ) Age = <1 Year Risk Factors For 1 Year Mortality VARIABLE NRelative Risk P-value95% Confidence Interval ECMO, diagnosis = congenital803.09< PRA > 10% ECMO, diagnosis = not congenital On dialysis Donor cause of death = cerebrovascular/stroke vs. head trauma Prior sternotomy < On ventilator < N = 902 Reference group = Congenital, no devices ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS ( ) Age = <1 Year Borderline Significant Risk Factors For 1 Year Mortality N = 902 ISHLT 2012 VARIABLEN Relative Risk P-value 95% Confidence Interval Infection requiring IV drug therapy (within 2wk/TX) Transplant year: vs J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS ( ) Age = <1 Year Risk Factors For 1 Year Mortality Continuous Factors (see figures) Recipient pre-transplant creatinineIschemia time Volume of pediatric transplants ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 1 Year Mortality in Age = <1 Year Recipient Pre-Transplant Creatinine p = ISHLT 2012 (N = 902) J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 1 Year Mortality in Age = <1 Year Ischemia time p = ISHLT 2012 (N = 902) J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 1 Year Mortality in Age = <1 Year Center Volume for Pediatric Transplants p = ISHLT 2012 (N = 902) J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS ( ) Age = 1-10 Years Risk Factors For 1 Year Mortality VARIABLE NRelative Risk P-value95% Confidence Interval ECMO Previous transfusion Diagnosis = congenital Donor cause of death = anoxia vs. head trauma N = 1,306 Reference group = Cardiomyopathy, no devices ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS ( ) Age = 1-10 Year s Borderline Significant Risk Factors For 1 Year Mortality N = 1,306 ISHLT 2012 VARIABLEN Relative Risk P-value 95% Confidence Interval Female recipient J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS ( ) Age = 1-10 Year s Risk Factors For 1 Year Mortality Continuous Factors (see figures) Recipient ageRecipient pre-transplant creatinine Recipient heightRecipient pre-transplant bilirubin Donor BSA J Heart Lung Transplant Oct; 31(10): ISHLT 2012

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 1 Year Mortality in Age = 1-10 Years Recipient Age p = ISHLT 2012 NOTE: Due to the correlation in donor size, recipient size and recipient age, the interpretation of the impact of each factor should be considered in the context of the other factors. (N = 1,306) J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 1 Year Mortality in Age = 1-10 Years Recipient Height p = NOTE: Due to the correlation in donor size, recipient size and recipient age, the interpretation of the impact of each factor should be considered in the context of the other factors. (N = 1,306) J Heart Lung Transplant Oct; 31(10): ISHLT 2012

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 1 Year Mortality in Age = 1-10 Years Donor BSA p = ISHLT 2012 NOTE: Due to the correlation in donor size, recipient size and recipient age, the interpretation of the impact of each factor should be considered in the context of the other factors. (N = 1,306) J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 1 Year Mortality in Age = 1-10 Years Recipient Pre-Transplant Creatinine p = (N = 1,306) J Heart Lung Transplant Oct; 31(10): ISHLT 2012

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 1 Year Mortality in Age = 1-10 Years Recipient Pre-Transplant Bilirubin p = (N = 1,306) J Heart Lung Transplant Oct; 31(10): ISHLT 2012

PEDIATRIC HEART TRANSPLANTS ( ) Age = Years Risk Factors For 1 Year Mortality VARIABLE NRelative Risk P-value95% Confidence Interval Retransplant Diagnosis = congenital Previous transfusion Donor cause of death = anoxia vs. head trauma N = 1,200 Reference group = Cardiomyopathy, no devices J Heart Lung Transplant Oct; 31(10): ISHLT 2012

PEDIATRIC HEART TRANSPLANTS ( ) Age = Year s Risk Factors For 1 Year Mortality Continuous Factors (see figures) Recipient pre-transplant bilirubinHeight ratio (borderline) ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 1 Year Mortality in Age = Years Recipient Pre-Transplant Bilirubin p = (N = 1,200) J Heart Lung Transplant Oct; 31(10): ISHLT 2012

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 1 Year Mortality in Age = Years Donor Height/Recipient Height Ratio p = ISHLT 2012 (N = 1,200) J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 5 Year Mortality VARIABLE NRelative Risk P-value95% Confidence Interval ECMO, age = 0 years782.50< ECMO, age = years Retransplant < Diagnosis = congenital < On dialysis PRA > 10% Male donor/female recip vs. male donor/male recip On ventilator N = 2,940 Reference group = Cardiomyopathy, no devices J Heart Lung Transplant Oct; 31(10): ISHLT 2012

PEDIATRIC HEART TRANSPLANTS ( ) Borderline Significant Risk Factors For 5 Year Mortality VARIABLE NRelative Risk P-value95% Confidence Interval Infection requiring IV drug therapy (within 2wk/TX) N = 2,940 Reference group = Cardiomyopathy, no devices J Heart Lung Transplant Oct; 31(10): ISHLT 2012

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 5 Year Mortality Continuous Factors (see figures) Recipient ageEstimated GFR (borderline) Volume of pediatric transplants (borderline) J Heart Lung Transplant Oct; 31(10): ISHLT 2012

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 5 Year Mortality with 95% Confidence Limits Recipient Age p = (N = 2,904) J Heart Lung Transplant Oct; 31(10): ISHLT 2012

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 5 Year Mortality with 95% Confidence Limits Center Volume for Pediatric Transplants p = (N = 2,904) J Heart Lung Transplant Oct; 31(10): ISHLT 2012

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 5 Year Mortality with 95% Confidence Limits Recipient Pre-Transplant Estimated GFR p = (N = 2,904) J Heart Lung Transplant Oct; 31(10): ISHLT 2012

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 10 Year Mortality VARIABLE NRelative Risk P-value95% Confidence Interval Retransplant < ECMO, age = 0 years On ventilator Diagnosis = congenital Male donor/female recip vs. male donor/male recip Transplant year: 1995/1996 vs. 1991/ vs. 4-6 total HLA mismatches Transplant year: 1999/2000 vs. 1991/ Transplant year: 1997/1998 vs. 1991/ < N = 3,263 Reference group = Cardiomyopathy, no devices J Heart Lung Transplant Oct; 31(10): ISHLT 2012

PEDIATRIC HEART TRANSPLANTS ( ) Borderline Significant Risk Factors For 10 Year Mortality VARIABLE NRelative Risk P-value95% Confidence Interval Balloon pump Diagnosis = not myopathy, congenital or retransplant Donor cause of death = anoxia vs. head trauma N = 3,263 Reference group = Cardiomyopathy, no devices ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 10 Year Mortality Continuous Factors (see figures) Donor ageRecipient weight Volume of pediatric transplants J Heart Lung Transplant Oct; 31(10): ISHLT 2012

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 10 Year Mortality with 95% Confidence Limits Donor Age p = ISHLT 2012 (N = 3,263) J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 10 Year Mortality with 95% Confidence Limits Recipient Weight p = ISHLT 2012 (N = 3,263) J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 10 Year Mortality with 95% Confidence Limits Center Volume for Pediatric Transplants p = ISHLT 2012 (N = 3,263) J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 15 Year Mortality VARIABLE NRelative Risk P-value95% Confidence Interval Retransplant Balloon pump Recipient history of malignancy On ventilator Diagnosis = congenital N = 2,113 Reference group = Cardiomyopathy, no devices ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 15 Year Mortality Continuous Factors (see figures) Donor ageVolume of pediatric transplants ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 15 Year Mortality with 95% Confidence Limits Donor Age p = ISHLT 2012 (N = 2,113) J Heart Lung Transplant Oct; 31(10):

PEDIATRIC HEART TRANSPLANTS ( ) Risk Factors For 15 Year Mortality with 95% Confidence Limits Center Volume for Pediatric Transplants p = ISHLT 2012 (N = 2,113) J Heart Lung Transplant Oct; 31(10):